Health & Biotech
Biocurious: Cashed up and pursuing the ‘c’ word, Imugene is on the verge of transforming cancer immunotherapy
Health & Biotech
‘One straightforward request’: Neurizon buoyant on FDA clarity
Health & Biotech
Health Check: With its last patient treated, Opthea eyes pending results of do-or-die trial
Health & Biotech
Dr Boreham’s Crucible: What’s all the fuss about biotech behemoth CSL?
Health & Biotech
Health Check: Brokers slash Cochlear valuations as customers hold tight on product upgrades
Health & Biotech
Recce soars on phase II skin infection trial results
Health & Biotech
Scott Power: Chemist Warehouse and Sigma officially say ‘I do’ as CSL & Cochlear feels heartache
Tech
Nvidia-powered computing firm Harrison.ai looks to expand to Europe, Middle East
Health & Biotech
Wellnex Life secures $9m to propel dual listing on London’s AIM market
Health & Biotech
Neurotech inks European development deal for cannabinoid therapies
Health & Biotech
Health Check: Despite a ‘biggest ever’ December half, Pro Medicus says it’s just revving up in the US
Health & Biotech
Rare opportunities – ASX health stocks tackling unmet medical needs
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.